Cystic Fibrosis Foundation

62 articles with Cystic Fibrosis Foundation

• Nanite Inc. Receives Up to $2M Investment from CF Foundation to Explore a Novel Method to Deliver Genetic Therapies to the Lung

  3/15/2023

  Nanite Inc. announced today an investment from the Cystic Fibrosis Foundation of up to $2 million to develop gene delivery technology.

• ReCode Therapeutics Announces Strategic Investment from the Cystic Fibrosis Foundation to Accelerate Development of Novel mRNA Therapy

  1/10/2023

  ReCode Therapeutics announced today that it will receive a strategic investment from the Cystic Fibrosis Foundation (CF Foundation) to develop ReCode’s inhaled mRNA-based therapeutic for people with cystic fibrosis (CF), including those with genotypes that do not respond to approved CFTR modulators.

• Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation

  12/12/2022

  Aridis Pharmaceuticals, Inc. today announced the Cystic Fibrosis Foundation invested $4.85 million in Aridis common stock on market terms under NASDAQ rules to support the ongoing development of AR-501, an inhalable broad-spectrum anti-infective currently under development for controlling debilitating chronic lung infections in cystic fibrosis (CF) patients.

• Cystic Fibrosis Foundation Announces Irena Barisic as Next Chief Operating and Financial Officer

  12/6/2022

  The Cystic Fibrosis Foundation announced that Irena Barisic has been appointed the next Executive Vice President, Chief Operating and Financial Officer.

• Cystic Fibrosis Foundation Invests $6M in Carbon Biosciences to Advance New Gene Therapy Approach for Cystic Fibrosis

  6/21/2022

  The Cystic Fibrosis Foundation announced its investment of $6 million in Carbon Biosciences to support the company‘s preclinical research into an innovative gene therapy approach for cystic fibrosis.

• Cystic Fibrosis Foundation Launches Inaugural Golden Ticket Competition to Find the Next Genetic Therapies for CF

  4/18/2022

  Cystic Fibrosis Foundation Launches Inaugural Golden Ticket Competition to Find the Next Genetic Therapies for CF.

• Bakar Labs and the Cystic Fibrosis Foundation Support Entrepreneurs to Develop New Genetic Therapies for CF

  4/18/2022

  Bakar Labs, the incubator at UC Berkeley's Bakar BioEnginuity Hub (BBH), announced today a unique collaboration with the Cystic Fibrosis Foundation to accelerate the application of new technologies for the treatment of cystic fibrosis.

• CF Foundation Funds Expansion of Clinical Trial Program for Potential Nonsense Mutations Therapy

  3/29/2022

  Today, the Cystic Fibrosis Foundation announced an award to Eloxx Pharmaceuticals Inc. for up to $15.9 million in additional funding to support the expansion of its ongoing ELX-02 clinical program focused on developing therapies for people with CF who have nonsense mutations.

• Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation

  3/29/2022

  Eloxx Pharmaceuticals, Inc. today announced that the Company has received additional funding of a Therapeutic Development Award of up to $15.9 million from the CF Foundation to support the ongoing ELX-02 clinical program.

• Cystic Fibrosis Foundation Invests in Felix Biotechnology as They Advance New Therapies Targeting Chronic Infections in Cystic Fibrosis

  3/3/2022

  Felix Biotechnology today announced it received a strategic investment from the Cystic Fibrosis Foundation as part of a Therapeutics Development Award.

• Cystic Fibrosis Foundation Announces Steven Rowe, MD, as Next Chief Scientific Officer

  1/26/2022

  Dr. Steven Rowe will support mission to cure cystic fibrosis by leading the Foundation’s research strategy, focusing on genetic therapies.

• Cystic Fibrosis Foundation Announces Investment in SalioGen Therapeutics to Fund Genetic Therapies Research

  1/5/2022

  The Cystic Fibrosis Foundation announced today that it has invested in SalioGen Therapeutics to support the company’s preclinical research into a novel genetic therapy for cystic fibrosis.

• Peptilogics Receives Award from the Cystic Fibrosis Foundation to Investigate PLG0301 and PLG0206 as Potential Dual-Acting Treatments for Lung Infections Associated with Cystic Fibrosis

  1/5/2022

  Peptilogics today announced that the company received an award from the Cystic Fibrosis Foundation.

• CF Foundation Awards Up to $5 Million to BiomX for Potential Phage Therapy

  1/4/2022

  Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance.

• Pulmocide Receives Investment from the Cystic Fibrosis Foundation

  12/6/2021

  Pulmocide Ltd. today announced a $3.5 million investment from the Cystic Fibrosis Foundation for the development of opelconazole for lung transplant recipients.

• CF Foundation Announces 2021 Impact Grant Recipients

  7/26/2021

  The Cystic Fibrosis Foundation announced the recipients of its sixth annual Impact Grants, which provide up to $10,000 of funding per year for up to two years to individuals and nonprofit organizations within the cystic fibrosis community who are leading projects to support people living with the disease.

• First-of-Its-Kind Study Uses Smartphone to Track Cystic Fibrosis in Real Life

  6/2/2021

  The Cystic Fibrosis Foundation announced the initiation of the HERO-2: Home Reported Outcomes Study, a first-of-its-kind, at-home observational study that aims to characterize the range of outcomes people experience while using Trikafta®.

• CF Foundation Funds Three New Research Awards to Advance its Path to a Cure Initiative

  5/27/2021

  New funding awards include up to $2.6M to Eloxx Pharmaceuticals to identify potential therapies for CF nonsense mutations

• 

  Israeli Company Grabs $28.5 Million for Restorative Cystic Fibrosis Treatment

  5/13/2021

  SpliSense, which focuses on cystic fibrosis and other genetic pulmonary diseases, closed on a $28.5 million Series B financing round. The company plans to use the money to advance its pipeline.

• Life Edit Therapeutics Announces Award from Cystic Fibrosis Foundation

  3/23/2021

  Company to use its novel gene editing technology to explore a potential in vivo gene therapy treatment for cystic fibrosis